Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure

By Mayer-Sonnenfeld Tehila   Har-Noy Michael   Lillehei Kevin O.   Graner Michael W.  

International Journal of Hyperthermia, Vol. 29, Iss. 6, 2013-09 ,pp. : 520-527

Informa Healthcare

Access to resources Recommend Favorite

The `peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity

By Graner Michael W.  

International Journal of Hyperthermia, Vol. 29, Iss. 5, 2013-08 ,pp. : 380-389

Informa Healthcare

Access to resources Recommend Favorite

Active Specific Immunotherapy with an Autologous Virus-modified Tumour Cell Vaccine in Human Renal Cell Carcinoma (RCC)

By Hinkel A.   de Riese W.   Alefelder J.   Laumann D.   Falkenberg F.W.   Senge T.   Hertle L.  

European Journal of Cancer, Vol. 31, Iss. 10, 1995-09 ,pp. : 1719-1720

Elsevier

Access to resources Recommend Favorite

Tumour-derived, Endocrine, Exogenous and Therapeutic Factors Differentially Modulate Cytokine Secretion in Whole Blood Cell Culture

By Fischer J.R.   Schindel M.   Lahm H.   Drings P.  

European Journal of Cancer, Vol. 33, Iss. 10, 1997-09 ,pp. : 1661-1667

Elsevier

Access to resources Recommend Favorite

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine

By Cohen L.   de Moor C.   Parker P.A.   Amato R.J.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 3, 2002-05 ,pp. : 119-124

Elsevier

Access to resources Recommend Favorite